Latest filings (excl ownership)
25-NSE
Exchange delisting
28 Jul 09
8-K
Bankruptcy or Receivership
13 Jul 09
8-K
Other Events
22 Jun 09
8-K
Cost Associated with Exit or Disposal Activities
16 Jun 09
8-K
Other Events
29 May 09
8-K
Oscient Pharmaceuticals Receives NASDAQ Letter Regarding
22 May 09
8-K
Other Events
19 May 09
8-K
Other Events
15 May 09
NT 10-Q
Notice of late quarterly filing
15 May 09
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
1 May 09
10-K/A
2008 FY
Annual report (amended)
30 Apr 09
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
29 Apr 09
8-K
Departure of Directors or Certain Officers
27 Mar 09
10-K
2008 FY
Annual report
25 Mar 09
8-K
Oscient Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results
25 Mar 09
8-K
Departure of Directors or Certain Officers
23 Mar 09
8-K
Cost Associated with Exit or Disposal Activities
13 Feb 09
S-1
IPO registration
13 Feb 09
8-K
Entry into a Material Definitive Agreement
3 Feb 09
8-K
Oscient Pharmaceuticals and Ethypharm SA File Lawsuit Against Lupin for Infringement of ANTARA® Patent
15 Jan 09
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Dec 08
8-K
Oscient Pharmaceuticals Announces Management Change
16 Dec 08
8-K
Oscient Pharmaceuticals Receives Paragraph IV
3 Dec 08
8-K
Oscient Pharmaceuticals Announces Successful Completion of Convertible Debt Exchange Offer
28 Nov 08
424B3
Prospectus supplement
25 Nov 08
424B3
Prospectus supplement
25 Nov 08
SC TO-I/A
Issuer tender offer statement (amended)
25 Nov 08
EFFECT
Notice of effectiveness
21 Nov 08
425
Business combination disclosure
20 Nov 08
8-K
Oscient Pharmaceuticals Announces Determination of the Consideration Issuable in its Exchange Offer
20 Nov 08
CORRESP
Correspondence with SEC
19 Nov 08
SC TO-I/A
Issuer tender offer statement (amended)
17 Nov 08
UPLOAD
Letter from SEC
13 Nov 08
10-Q
2008 Q3
Quarterly report
10 Nov 08
425
Business combination disclosure
7 Nov 08
8-K
Oscient Pharmaceuticals Amends Exchange Offer
7 Nov 08
SC TO-I/A
Issuer tender offer statement (amended)
7 Nov 08
Latest ownership filings
No filings